ClinicalTrials.gg
RecruitingNCT07149090Updated Nov 4, 2026

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

A Phase 1/2 interventional study of Lenvatinib in STOMACH NEOPLASM, Gastric Cancer and Gastric Cancer Adenocarcinoma Metastatic, sponsored by Asan Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Asan Medical Center · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies testing lenvatinib in Stomach Neoplasms — 9 open to participants now, 11 under way, none of them phase 3. lenvatinib · Stomach Neoplasms.

Planned enrollment
5th of 15
61 · median 42
Started
2025
with 1 other
Phase 1/2
Only one
of the 15
Primary completion
2027-07
later than 8 of 10 live
Registered
13th of 15
by date
Lead sponsor
1 of 15
Asan Medical Center

Among the 15 studies testing lenvatinib in Stomach Neoplasms, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is the only one in phase 1/2, reaches primary completion later than 8 of the 10 other live ones, and was the 13th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 15 studies testing lenvatinib in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing lenvatinib in Stomach Neoplasms, or all of them as a file.
02

Study summary

To investigate efficacy and safety of lenvatinib in combination with nivolumab plus chemotherapy in gastric cancer patients with peritoneal metastasis and grade ≥ 2 ascites.

Read the detailed description

Gastric cancer is the 4th leading cause of cancer-related mortality and the 5th most common malignancy worldwide. The past decade has seen significant progress in first-line systemic chemotherapy for patients with advanced gastric cancer. Immune checkpoint inhibitor (ICI)-based chemotherapy has become the standard first-line treatment since the demonstration of improved overall survival (OS) due to nivolumab plus chemotherapy in the Checkmate-649 study. Subsequent phase 3 trials have also demonstrated the positive impact of adding ICI to chemotherapy on survival. However, a proportion of patients still show poor survival outcomes with first-line ICI plus chemotherapy, highlighting an unmet need to improve treatment outcomes in such patients.

While patients with microsatellite instability (MSI)-high gastrointestinal cancers exhibit favorable outcomes with ICIs, MSI-high gastrointestinal cancers with peritoneal metastases and ascites exhibited highly unfavorable outcomes to ICI-based therapies. To this end, a research team analyzed the survival outcomes of gastric cancer patients treated with first-line nivolumab plus chemotherapy, finding that patients with peritoneal metastasis and grade ≥ 2 ascites had detrimental survival outcomes despite a high PD-L1 CPS (≥5). Ascites VEGF level was reportedly high in patients with a large amount of malignant ascites, supporting the concept that anti-VEGF therapies are promising for treating gastric cancer patients with peritoneal metastasis.

Lenvatinib is a potent multiple RTKi that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), FGFR1-4, PDGFRα, c-KIT, and RET, which is approved for use in various cancer types, including hepatocellular carcinoma. Among known kinase inhibitors in clinical use, lenvatinib is one of the only inhibitors currently labeled with a mechanism of action as an inhibitor of not only VEGFRs but also FGFRs, both of which are currently believed to be very important for tumor angiogenesis.

It is hypothesized that the addition of lenvatinib to nivolumab plus chemotherapy in gastric cancer patients with peritoneal metastasis and grade ≥ 2 ascites could improve survival outcomes for these patients. A prospective phase Ib/II trial has been designed to investigate the efficacy and safety of lenvatinib in combination with nivolumab plus chemotherapy in gastric cancer patients with peritoneal metastasis and grade ≥ 2 ascites.

03

Conditions studied

  • STOMACH NEOPLASM
  • Gastric Cancer
  • Gastric Cancer Adenocarcinoma Metastatic

Browse trials for

Keywords

  • Stomach Neoplasms
  • Gastric cancer
  • Lenvatinib
  • Advanced Gastric Cancer
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed proven , unresectable or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma
  2. Positive for peritoneal metastasis and grade ≥ 2 malignant ascites as confirmed by computed tomography (CT)
  3. combined positive score of ≥5 based on the 28-8 assay
  4. Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations
  5. Age > 19 years at time of study entry
  6. (ECOG) performance status of 0 or 1
  7. of > 4 months
  8. Body weight > 30kg
  9. No existing neuropathy
  10. Adequate normal organ and marrow function as defined below:

    • ≥9.0 g/dL
    • (ANC) 1.5 x (> 1500 per mm3)
    • count ≥100 (or 75) x 109/L (>75,000 per mm3)
    • Serum ≤1.5 x institutional (ULN)
    • (SGOT)/ALT (SGPT) ≤2.5 x institutional ULN
    • Measured (CL) > 40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance:
  11. Evidence of status or negative urinary or serum pregnancy test for female pre- menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
  12. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Exclusion criteria

Exclusion Criteria:

  1. Disease progression within 6 months after completion of chemotherapy.
  2. Participation in another clinical study with an product during the last 2 weeks
  3. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  4. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
  5. Major surgical procedure within 28 days prior to the first dose
  6. Unable to take medication orally
  7. Gastrointestinal bleeding
  8. Impaired bowel absorption
  9. History of allogenic organ transplantation
  10. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written
  11. History of another primary except for

    • Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose and of low potential risk for recurrence
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease
  12. History of active primary immunodeficiency
  13. Active infectious disease
  14. Tuberculosis (based on clinical history, physical examination, radiographic findings, and TB testing in line with local practice)
  15. (known positive HBV surface antigen (HBsAg) result)
  16. (patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA)
  17. (positive HIV 1/2 antibodies)
  18. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible.
  19. Female patients who are pregnant or breastfeeding, as well as male or female patients of who are not willing to use effective from the time of screening until 5 months following the final dose of lenvatinib.
  20. Known allergy or to the investigational drug or any of its components.
  21. Patients with known deficiency of dihydropyrimidine dehydrogenase (DPD).
  22. Patients with known hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (estimated)

Study arms

  • Experimental
    Lenvatinib+Nivolumab+Chemotherapy(Capecitabine+Oxaliplatin)

    Drug: Lenvatinib

Interventions

  • Description: Lenvatinib: 12 mg (for body weight ≥ 60 kg) or 8 mg (for body weight \< 60 kg) per oral once daily * Dose level 1: 8mg per oral once daily (for \<60kg) 12mg per oral once daily (for ≥ 60kg) * Dose level 2: 4mg per oral once daily (for \<60kg) 8mg per oral once daily (for ≥ 60kg) Nivolumab: 360 mg administered intravenously every 3 weeks Chemotherapy(Oxaliplatin+Capecitabine) every 3 weeks * Capecitabine 1000 mg/m² per oral twice daily on Days 1-14 * Oxaliplatin 130 mg/m² administered intravenously on Day 1

    Also known as: Nivolumab+Chemotherapy(Capecitabine+Oxaliplatin)

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Phase 1b part: Recommend phase 2 dose(RP2D)

    Phase 1b part: will follow a traditional 3+3 dose-escalation design. Dose-limiting toxicities (DLTs) will be assessed after the first 3 subjects are enrolled. If no DLTs are observed among the initial 3 subjects, the dose level will be considered the recommended phase 2 dose (RP2D). If 1 of the initial 3 subjects experiences a DLT, 3 additional subjects will be enrolled at the same dose level (for a total of 6 subjects). If ≤1 of 6 subjects experience a DLT, the dose level will be defined as the RP2D. Up to 12 subjects may be enrolled in the Phase 1b part.

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  2. Phase II part: 6 month progression-free survival (PFS) rate

    6 month progression-free survival (PFS) rate

    Time frame: At 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.

Of 67 non-industry phase 1/2 interventional studies under Stomach Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 133. This study's planned 20 months is below that.

Counting every sponsor, half of 158 studies reached it within 60 months; a quarter within 40 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 29, 2025
StartActual
Nov 11, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07149090
Responsible party
Hyung-Don Kim (Assistant Professor, Asan Medical Center) — Principal investigator
First posted
Aug 29, 2025
Start date
Nov 11, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Hyung-Don Kim
Contact
kimhdmd@amc.seoul.kr
82-2-3010-0236
Jaewon Hyung
Contact
musicine123@gmail.com
82-2-3010-1464

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion